Get started
Author

Philippe Rey

Observed name: Rey Philippe
ORCID: 0009-0007-2833-1011
Observed ORCID: 0009-0007-2833-1011
OpenAlex ID: A5028490703
Measurable Residual Disease–Guided Therapy in Newly Diagnosed Myeloma
2025 · Aurore Perrot, Jérôme Lambert, et al. · New England Journal of Medicine · 85
Apixaban for the prevention of thromboembolism in immunomodulatory‐treated myeloma patients: Myelaxat, a phase 2 pilot study
2019 · Brigitte Pegourie, Lionel Karlin, et al. · American Journal of Hematology · 62
First Results of the Acsé Pembrolizumab Phase II in the Primary CNS Lymphoma (PCNSL) Cohort
2020 · Khe Hoang-Xuan, Roch Houot, et al. · Blood · 58
Isatuximab, carfilzomib, lenalidomide, and dexamethasone induction in newly diagnosed myeloma: analysis of the MIDAS trial
2025 · Aurore Perrot, Cyrille Touzeau, et al. · Blood · 41
Improved survival in multiple myeloma during the 2005–2009 and 2010–2014 periods
2021 · Jill Corre, Aurore Perrot, et al. · Leukemia · 32
PDF
Prognostic impact of translocation t(14;16) in multiple myeloma according to the presence of additional genetic lesions
2023 · Anaïs Schavgoulidze, Aurore Perrot, et al. · Blood Cancer Journal · 29
PDF
High-risk genomic consensus validation for patients with newly diagnosed multiple myeloma using next-generation sequencing
2025 · Anaïs Schavgoulidze, Aurore Perrot, et al. · Blood · 21
Utility of post-therapy brain surveillance imaging in the detection of primary central nervous system lymphoma relapse
2016 · Gaëlle Fossard, Céline Ferlay, et al. · European Journal of Cancer · 17
RAS/RAF landscape in monoclonal plasma cell conditions
2024 · Anais Schavgoulidze, Jill Corre, et al. · Blood · 14
Clinical outcome of therapy‐related acute myeloid leukemia patients. Real‐life experience in a University Hospital and a Cancer Center in France
2023 · Amine Belhabri, Mael Heiblig, et al. · Cancer Medicine · 6
PDF
Impact of the introduction of rituximab in first‐line follicular lymphoma: a retrospective study of 247 unselected patients referred to a single institution with a long‐term follow‐up
2014 · Emmanuelle Nicolas‐Virelizier, Céline Ségura‐Ferlay, et al. · Hematological Oncology · 5
Usefulness of Positron Emission Tomography Using 18F-FDG Performed At Diagnosis and During Initial Chemotherapy for Imaging Primary Central Nervous System Lymphoma: A 24 Immunocompetent patient's Study.
2011 · Herve Ghesquieres, Céline Ferlay, et al. · Blood · 5
Individualised physical activity programme in patients over 65 years with haematological malignancies (OCAPI): protocol for a single-arm feasibility trial
2021 · Baptiste Fournier, Emmanuelle Nicolas-Virelizier, et al. · BMJ Open · 4
PDF
Infradiaphragmatic Hodgkin lymphoma: a large series of patients staged with PET-CT
2017 · Cédric Rossi, Morgane Mounier, et al. · Oncotarget · 4
PDF
Rituximab in combination with adapted-dose of ifosfamide and etoposide as salvage treatment in elderly refractory/relapsed diffuse large B-cell lymphoma patients non-candidate for high dose therapy: a retrospective study
2021 · Guillaume Aussedat, Delphine Maucort-Boulch, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 3
Impact of the total lesion glycolysis ( TLG ) in predicting response of follicular lymphoma to rituximab
2024 · Paul Emile Pignot, Haifa Bahri, et al. · British Journal of Haematology · 2
Evaluation in the Context of Daily Practice of Follicular Lymphoma patients' Outcome Before and After Approval of Rituximab in First Line Therapy in This Indication: Results of a Retrospective Analysis of 247 Unselected Patients with a 5-Year Median of Follow-up,
2011 · Emmanuelle Nicolas Virelizier, Celine Segura-Ferlay, et al. · Blood · 2
Detection of potential complications in cancer survivors after chemotherapy and development of a regional care network: the PASCA feasibility study
2025 · Romain Buono, Olivia Pérol, et al. · Frontiers in Medicine · 1
Recommandations 2024 de l’Intergroupe francophone du myélome sur la prise en charge des gammapathies monoclonales de signification indéterminée
2024 · Laure Vincent, Murielle Roussel, et al. · Hématologie · 1
Diagnosis-to-Treatment Interval Is an Important Prognostic Factor with a Time-Dependent Effect Predicting Event-Free Survival after 12 Months from First-Line Treatment in Newly Diagnosed Diffuse Large B-Cell Primary CNS Lymphoma
2020 · Marie-Charlotte Laude, Edith Julia, et al. · Blood · 1
Personalised Follow-up Program after Acute Phase of Treatment in Oncology/Hematology Patients Towards Early Intervention, Better Care and Quality of Life Improvement: Results from Pasca Pilot Study
2019 · Mauricette Michallet, Mohamad Sobh, et al. · Blood · 1
Impact of the Use of Polymerase Chain Reaction for the Diagnosis and Management of Pneumocystis Jirovecii Pneumoniae in a Retrospective Cohort of Patients with Lymphoid Malignancies
2016 · Felicite De Charry, Damien Dupont, et al. · Blood · 1
Combination of Rituximab with Chemotherapy Improved Outcome of Newly Diagnosed Primary CNS Lymphoma: A Retrospective Study of 209 Unselected Patients Referred to a Single Institution
2015 · Herve Ghesquieres, Celine Segura-Ferlay, et al. · Blood · 1
Utility Of Post Therapy Brain Surveillance Imaging In The Detection Of Primary CNS Lymphoma (PCNSL) Relapse
2013 · Gaelle Fossard, Emmanuelle Nicolas-Virelizier, et al. · Blood · 1
Prognostic Value of 18F-FDG Positron Emission Tomography Used for Assessment of the First Line Therapy in 410 Diffuse Large B-Cell Lymphoma Patients: A Daily Practice Evaluation Before and After the Prescription of This Metabolic Imaging Technique,
2011 · Herve Ghesquieres, Céline Ferlay, et al. · Blood · 1
Works count: 48
Citation count: 400
H-index: 9
I10-index: 9
Year
Topic
Type